Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as TAP-144-SR(6M)
TAP-144 · 2 trials · 2 indications
Comparison of both the treatment groups was done by assessing the suppressive effect on serum E2 concentration maintained at menopausal level (=\<30pg/mL). Suppression rate was calculated as proportion of participants maintained at menopausal level.
Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)
| Arm | Type | Description |
|---|---|---|
| TAP-144-SR(6M) | EXPERIMENTAL | TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 96 weeks. |
| TAP-144-SR(3M) | ACTIVE_COMPARATOR | TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 96 weeks. |
| Name | Type | Description |
|---|---|---|
| TAP-144-SR(6M) | DRUG | - |
| TAP-144-SR(3M) | DRUG | - |
Inclusion Criteria: 1. The participant has histopathologically-confirmed primary breast cancer in Japanese. 2. The participant is aged 20 years or older when informed consent is obtained 3. The participant has estrogen receptor (ER)-positive tumor cells and/or progesterone receptor (PgR)-positive p...
TAP-144 is an investigational small molecule oncology drug developed by Takeda Pharmaceutical Company Limited. It is being studied in Phase 3 clinical trials for premenopausal breast cancer and prostate cancer. The drug is also known as TAP-144-SR(6M). It has been evaluated in Japan in randomized, active-controlled trials.
TAP-144 is being studied for use in premenopausal breast cancer. A Phase 3 trial (NCT01546649) evaluated TAP-144-SR(6M) in postoperative and hormone therapy-naive patients with premenopausal breast cancer. The trial enrolled 167 female patients aged 20 years and older in Japan and has been completed.
TAP-144 is being studied for use in prostate cancer. A Phase 3 trial (NCT01546623) evaluated TAP-144-SR(6M) in prostate cancer patients previously treated with hormonal therapy. The trial enrolled 160 male patients aged 20 years and older in Japan and has been completed.
TAP-144 is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the Phase 3 clinical trials evaluating TAP-144-SR(6M) in premenopausal breast cancer and prostate cancer.
TAP-144 is in Phase 3 clinical development. It has been evaluated in two completed Phase 3 trials, one in premenopausal breast cancer and one in prostate cancer. TAP-144 is investigational and has not been approved by the FDA.
TAP-144 has been studied in two completed Phase 3 trials. NCT01546649 evaluated TAP-144-SR(6M) in postoperative and hormone therapy-naive patients with premenopausal breast cancer, enrolling 167 patients. NCT01546623 evaluated TAP-144-SR(6M) in prostate cancer patients previously treated with hormonal therapy, enrolling 160 patients. Both trials were conducted in Japan.
Yes, TAP-144-SR(6M) is an alternative name for TAP-144. The two names refer to the same drug candidate developed by Takeda Pharmaceutical Company Limited. TAP-144-SR(6M) is the name used in the Phase 3 clinical trial titles for both premenopausal breast cancer and prostate cancer.